Trial Profile
Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Fludarabine; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 13 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2019.
- 13 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.